Emmes is excited to share the significant progress being made in clinical studies we undertake for clients and to give you a look inside some of our own news.
Seven Emmes Employees Recognized in Lancet Study Comparing Two Opioid Treatments
The Emmes Corporation today announced its participation in a three-year study testing the results of two different opioid treatment medications. The research, published in one of the world’s oldest and best known medical journals, concluded that for those able to begin treatment, both drugs are nearly equal in their safety and effectiveness. The National Institute on Drug Abuse (NIDA) funded the research. In addition to providing data management and statistical support, Emmes served as the clinical coordinating center. This involved protocol development, pharmacovigilance, quality assurance, safety monitoring and regulatory support. The clinical trial occurred between 2014 to 2017 at eight community treatment programs across the U.S. A total of 570 patients participated, with each group followed for a 24-week period.
New Research Links Umbilical Cord Blood to Motor Function Improvement in Children with Cerebral Palsy
The Emmes Corporation today announced its statistical and data management support of a clinical trial that offers new hope for children with cerebral palsy (CP). Stephen Wease and Dr. Beth Blackwell joined a team of prominent researchers from Duke University Medical Center to test whether umbilical cord blood would improve motor skills function in children suffering from the disorder. According to Wease, Emmes project leader, “The phase II trial showed promising results, and we’re eager for the next phases of research to further our understanding of this encouraging new mechanism for treating children with CP.”
The Washington Business Journal Recognizes Emmes in Two "Top Company" Lists
The Emmes Corporation today announced that it was named one of the top women-owned businesses in the Washington metropolitan area by the Washington Business Journal. The company was ranked as the seventh largest women-owned business in the Washington region, up from number eight last year. Emmes was also included as one of the Washington Business Journal’s Top 100 private companies in September. Last year’s revenues were $90 million, and the company now has more than 600 employees.
The Emmes Corporation Wins $70 Million Contract for Pediatric Research
The Emmes Corporation today announced that it was awarded a contract from the National Institutes of Health to support pediatric clinical trials sponsored by the National Institute of Child Health and Human Development (NICHD). Valued at nearly $70 million, the 10-1/2 year contract will support the NIH’s effort to improve the labeling of drugs for pediatric use. The company’s role as the data coordinating center involves study design, data management, regulatory support, pharmacovigilance, site monitoring, and statistical analyses.
Emmes Recognized in Eye Disease Research Published by the Journal of the American Medical Association
The Emmes Corporation today announced that Dr. Paul VanVeldhuisen, chief operating officer and principal investigator, co-authored a study published by the Journal of the American Medical Association (JAMA). The study focused on the efficacy and safety of a commonly used, off-label drug called Avastin in treating macular edema due to central retinal vein occlusion. The study also addressed how Avastin compared to another drug, Eylea, which has been approved by the FDA and is being used to treat the same disease. The 2-1/2-year study with nearly 400 patients concluded that Avastin was as effective as Eylea in improving vision after six months of treatment. The cost of Avastin is $60 per dose compared to Eylea’s $1,850 per dose.
Emmes Expands Zika Research
The Emmes Corporation today announced a contract spanning just over four years for a Phase 2 study of a Zika vaccine. The contract, valued at up to $27.6 million, expands the initial Phase 1 testing that began last year. This is the first-ever Phase 2 study for a Zika vaccine. Dr. Anne Lindblad, president and chief executive officer of Emmes, said, “The win is important because it expands our role in combating the Zika virus, a significant and enduring public health challenge.”
Emmes Reports Record Growth in 2016
The Emmes Corporation today announced the highest revenues in its 40‐year history along with significant growth in its employee count. Revenues surpassed $90 million in 2016, and it employed 567 employees in its U.S. and international offices.
Research on traumatic brain injury in the military highlighted in Undersea and Hyperbaric Medicine Journal
The Emmes Corporation today announced that a large team of scientists and health professionals including those from the company, LDS Hospital in Salt Lake City, Utah, Lovelace Biomedical Environmental Research Institute in Albuquerque, New Mexico, and the U.S. Army Medical and Materiel Development Activity at Fort Detrick, Maryland, have authored a series of papers summarizing significant research on traumatic brain injury in the military.
Data Analysis Conducted by Emmes Contributed to New NIH Research Linking Air Pollution to Preterm Birth Risks in Mothers with Asthma
The Emmes Corporation today announced that it contributed to a landmark research study by the National Institutes of Health linking air pollution and preterm birth risk in pregnant women with asthma. The study, published in the Journal of Allergy and Clinical Immunology, reported that pregnant women with asthma have an increased risk for preterm birth when exposed to high levels of nitrogen oxides and carbon monoxide, common traffic-related air pollutants.
Dr. Paul VanVeldhuisen Named Chief Operating Officer of The Emmes Corporation
The Emmes Corporation today announced that Dr. Paul VanVeldhuisen has been promoted to the newly created position of chief operating officer. Dr. VanVeldhuisen, who started at Emmes as a statistician and epidemiologist, will assume the additional leadership responsibilities while continuing to serve as principal investigator for government and privately funded research projects.
Research Shows Lithium as an Effective Treatment for Pediatric Bipolar Disorder
The Emmes Corporation today announced that three of its statisticians, Dr. Ravinder Anand, Dr. Traci Clemons and Karen Martz, co-authored a pivotal study that examined lithium as a treatment for pediatric bipolar I disorder. The study was published in the October issue of Pediatrics.
Emmes Recognized in New Research Published by the Journal of the American Medical Association
The Emmes Corporation today announced that one of its principal investigators and statisticians, Dr. Traci Clemons, co-authored a study that was just published by the Journal of the American Medical Association (JAMA).